capecitabine,temozolomide
roche,merck
['dear']
 dear i would say it is a possible option and the only trial that showed an improvement in mos.
however, i would consider it only in fit patients.
MD-PhD, MSc
Passionate Oncologist
Focus on Molecular Oncology 
Focus on Gastrointestinal Oncology